News + Resources

Keep up with the latest

Featured

This Scientist Is Building Custom Gene-Editing Tools

This Scientist Is Building Custom Gene-Editing Tools

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

CRISPR 2.0, the Next Generation

June 21, 2024

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

TEDxBerkeley

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target

February 7, 2024

Scrip

Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target

February 7, 2024

All Stories

All
News
Press Releases
News

Sanofi taps Scribe for in vivo partnership worth more than $1.2B biobucks aimed at sickle cell and beyond

July 18, 2023

Fierce Biotech

Read Now
News

Sanofi licenses CRISPR enzyme in bid to develop safer, simpler sickle cell cure

July 18, 2023

STAT News

Read Now
News

Sanofi, Doudna-founded Scribe Therapeutics to target sickle cell disease in new pact

July 17, 2023

Endpoints News

Read Now
News

Sanofi and Scribe’s expanded deal builds path to in vivo editing in SCD

July 17, 2023

BioCentury

Read Now
News

Sanofi goes back to Scribe

July 17, 2023

Evaluate

Read Now
News

Sanofi expands research deal with gene editing startup Scribe

July 17, 2023

Biopharma Dive

Read Now
Press release

Scribe Therapeutics to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days

March 31, 2023

Read Now
Press release

Scribe Therapeutics to Participate in Four Upcoming Conferences

November 17, 2022

Read Now
Press release

Scribe Therapeutics to Participate in Upcoming Investor Conferences

September 29, 2022

Read Now
Press release

Scribe Therapeutics Announces Research Collaboration with Sanofi to Accelerate Breakthrough CRISPR-based Cell Therapies for Cancer

September 27, 2022

Read Now
Press release

Scribe Therapeutics Announces Expansion of San Francisco Bay Area Headquarters, 3 Key Senior Hires

July 26, 2022

Read Now
Press release

Scribe Therapeutics to Participate in SVB Securities Biopharma Private Company Connect

July 15, 2022

Read Now

Publications and presentations